Bausch+Lomb Results Presentation Deck
Segment Reported Revenue
Vision Care ³
Contact Lens Revenue
Consumer Revenue
Total Revenue
Surgical²
Implantables Revenue
Equipment Revenue
Consumables Revenue
Total Revenue
Ophthalmic Pharmaceuticals ³
Total Revenue
BAUSCH + LOMB
1.
2.
3.
1Q23
$226M
$361M
$587M
1Q23
$44M
$44M
$95M
$183M
1Q23
$161 M
1Q22
$215M
$345M
$560M
1Q22
$45M
$42M
$87M
$174M
1Q22
$155M
Reported Change
5%
5%
5%
Reported Change
(2%)
5%
9%
5%
Reported Change
4%
Constant Currency
Change %¹
10%
8%
8%
Constant Currency
Change %¹
2%
7%
13%
9%
Constant Currency
Change %¹
7%
This is a non-GAAP measure or ratio. See Slide 1 and this Appendix for further information on non-GAAP measures and ratios.
As of the first quarter of 2023, certain products were recategorized across the consumables, impantables and equipment product categories. This change was made as management believes this better aligns these products in their respective
categories. Prior period presentations of product categories have been conformed to current product category structure to allow investors to evaluate results between periods on a consistent basis.
Effective in the first quarter of 2023, certain products historically included in the reported results of the Ophthalmic Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in
the reported results of the Vision Care segment are now included in the reported results of the Ophthalmic Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the
groupings of similar products. The net impact of these product movements was not material to the periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure.
23View entire presentation